Inspire Investing LLC increased its position in Ingevity Co. (NYSE:NGVT – Free Report) by 8.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,013 shares of the company’s stock after buying an additional 596 shares during the period. Inspire Investing LLC’s holdings in Ingevity were worth $350,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. First Horizon Advisors Inc. boosted its holdings in Ingevity by 809.2% in the 2nd quarter. First Horizon Advisors Inc. now owns 591 shares of the company’s stock worth $26,000 after buying an additional 526 shares during the period. TFO Wealth Partners LLC boosted its holdings in Ingevity by 40,750.0% in the 4th quarter. TFO Wealth Partners LLC now owns 817 shares of the company’s stock worth $39,000 after buying an additional 815 shares during the period. Blue Trust Inc. boosted its holdings in Ingevity by 101.8% in the 2nd quarter. Blue Trust Inc. now owns 896 shares of the company’s stock worth $43,000 after buying an additional 452 shares during the period. Headlands Technologies LLC bought a new position in Ingevity in the 2nd quarter worth $46,000. Finally, Everence Capital Management Inc. bought a new position in Ingevity in the 2nd quarter worth $180,000. Institutional investors own 91.59% of the company’s stock.
Ingevity Stock Down 1.7 %
Shares of NYSE NGVT opened at $39.37 on Tuesday. The firm’s 50-day moving average price is $39.29 and its 200-day moving average price is $44.43. The company has a current ratio of 1.92, a quick ratio of 1.07 and a debt-to-equity ratio of 4.92. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -12.66 and a beta of 1.62. Ingevity Co. has a 12-month low of $32.21 and a 12-month high of $56.29.
Wall Street Analyst Weigh In
NGVT has been the subject of several recent analyst reports. Oppenheimer dropped their target price on shares of Ingevity from $58.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Wells Fargo & Company decreased their price target on shares of Ingevity from $45.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, August 5th. CJS Securities upgraded shares of Ingevity from a “market perform” rating to an “outperform” rating and set a $58.00 price target on the stock in a research note on Wednesday, August 7th. Finally, BMO Capital Markets decreased their price target on shares of Ingevity from $45.00 to $42.00 and set a “market perform” rating on the stock in a research note on Monday, August 5th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.33.
Read Our Latest Stock Analysis on NGVT
About Ingevity
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Featured Articles
- Five stocks we like better than Ingevity
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Average 401k Balance by Age Explained
- What Investors Need to Know About Upcoming IPOs
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the Nikkei 225 index?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.